PURPOSE: To overcome cytochrome P __number__ D __number__ (CYP __number__ D __number__ ) mediated tamoxifen resistance in postmenopausal early breast cancer, CYP __number__ D __number__ phenotype-adjusted tamoxifen dosing in patients with impaired CYP __number__ D __number__ metabolism and/or the application of endoxifen, the most potent tamoxifen metabolite, are alternative treatment options.